Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Ferdinandos Skoulidis, Bob T. Li, Grace Kho Dy et al. · New England Journal of Medicine · 2021
BACKGROUND: p.G12C-mutated advanced solid tumors in a phase 1 study, and particularly promising anticancer activity was observed in a subgroup of patients with non-small-cell lung cancer (NSCLC). METHODS: p.G12C-mutated advanced NSCLC previously treated with standard therapies. The primary end point was objective response (complete or partial response) according to independent central review. Key secondary end points included duration of response, disease control (defined as complete response, partial response, or stable disease), progression-free survival, overall survival, and safety. Exploratory biomarkers were evaluated for their association with response to sotorasib therapy. RESULTS: . CONCLUSIONS: p.G12C-mutated NSCLC. (Funded by Amgen and the National Institutes of Health; CodeBreaK100 ClinicalTrials.gov number, NCT03600883.).
Cited by 1,809 works. doi:10.1056/nejmoa2103695 Open-access PDF
Authors
- Ferdinandos Skoulidis
- Bob T. Li
- Grace Kho Dy
- Timothy Jay Price
- Gerald Steven Falchook
- Jürgen Wolf
- Antoîne Italiano
- Martin Schüler
- Hossein Borghaei
- Fabrice Barlési
- Terufumi Kato
- Alessandra Curioni Fontecedro
- Adrian Gerold Sacher
- Alexander I. Spira
- Suresh S. Ramalingam
- Toshiaki Takahashi
- Benjamin Besse
- Abraham Anderson
- Agnes Lee Ang
- Qui Tran
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Cancer Statistics, 2021
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer